Shanghai, China – Recently, MicroPort NeuroScientific Corporation (02172.HK, “MicroPort® NeuroScientific”) today announced that its subsidiary, MicroPort NeuroTech (Shanghai) Co., Ltd., has received official acceptance into the Green Channel special review pathway for innovative medical devices by the National Medical Products Administration (NMPA) for its StraitPass™ Disposable Aspiration Neuroendoscope Device (“StraitPass™”).
StraitPass™ is an innovative single-use neuroendoscopic device developed to support the removal of hematomas in patients with cerebral hemorrhage. By integrating advanced visual imaging and aspiration capabilities, it enables surgeons to locate and evacuate blood clots with greater precision, while minimizing damage to surrounding healthy brain tissue.
Hypertensive intracerebral hemorrhage (ICH) accounts for approximately 70% of such cases in China. Many occur deep within the basal ganglia, a central region of the brain responsible for essential functions including motor control, cognition, and emotion. Hematoma formation in these areas often leads to mass effect and toxic reactions, contributing to persistently high rates of disability and mortality among stroke patients.
The StraitPass™ system is designed to navigate these challenging anatomical zones and provide clinicians with a new tool for minimally invasive hematoma evacuation, with the goal of improving clinical outcomes and reducing surgical trauma.
With this latest acceptance, four products from MicroPort NeuroScientific have now been granted access to the Green Channel, including the Tubridge® Flow Diverter, Bridge® Rapamycin Target Eluting Vertebral Stent System, and Rebridge® Intracranial Artery Stent. The designation reflects the company's continued innovation in the field of neurovascular intervention and its commitment to advancing technologies that address critical unmet needs in stroke and hemorrhage management.
About MicroPort NeuroScientific
MicroPort NeuroScientific (MicroPort NeuroScientific Corporation; HKEX: 2172), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is committed to the research and development of high-end medical devices in the field of neurological interventional treatment with solutions that currently support over 120 cerebrovascular stenting procedures every day. In the future, MicroPort NeuroScientific will continue investing more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro-interventional solutions for physicians and patients.
More information is available at: https://www.microportneurosci.com/